{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:25:59Z","timestamp":1792106759818,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>As a new immunomodulator for rheumatoid arthritis, iguratimod (IGU) also has therapeutic potential in other immune diseases. In this study, we determined the effects of IGU on disease control in patients with palindromic rheumatism (PR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with PR were divided into Control group (Ctrl group) and an IGU treatment (IGU group) groups. Drug efficacy was evaluated according to the frequency of PR attacks (monthly), the visual analog scale (VAS) score of patient pain, and clinical symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The drug positivity and disease control rates of the IGU group (100.00% and 90.91%, respectively) were significantly higher than those of the Ctrl group (61.11% and 5.56%; <jats:italic>p<\/jats:italic>\u2009=\u2009.002 and <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001, respectively). The median number of PR flares and the VAS score of patients in the Ctrl group decreased from 3.00 (1.00\u201315.00) to 0.83 (0.00\u201312.00) and from 5 (4\u20136) to 4 (1\u20136), respectively. In the IGU group, the median number of PR attacks decreased from 4.50 (2.00\u201315.00) to 0.00 (0.00\u20130.33), and the VAS score decreased from 5 (4\u20136) to 0 (0\u20132). The IGU group exhibited a significant reduction in PR flare frequency and improvement in the VAS value (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001 and <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study is the first to describe the efficacy of IGU in PR treatment. IGU can significantly reduce the number of PR flares and improve the clinical symptoms of patients with PR.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.932","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T11:50:31Z","timestamp":1687953031000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iguratimod efficacy in palindromic rheumatism treatment"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-1999","authenticated-orcid":false,"given":"Fangfang","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Rheumatism and Immunology Ningbo No. 6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Ningbo NO.6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology Ningbo No. 6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology Ningbo No. 6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixia","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology Ningbo No. 6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology Ningbo No. 6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology Ningbo No. 6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-735X","authenticated-orcid":false,"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Ningbo NO.6 Hospital Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90177-D"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.09.014"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090025"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.36.1.56"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009748709165412"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg268"},{"issue":"11","key":"e_1_2_11_8_1","first-page":"2319","article-title":"HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis","volume":"29","author":"Maksymowych WP","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2554"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg381"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200804010-00008"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-006-0542-y"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0308-5"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14868"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2569-3"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120995"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04578-2"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2021.20062"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2019.01.002"},{"issue":"12","key":"e_1_2_11_20_1","first-page":"2591","article-title":"Inhibitory effect of T\u2010614 on tumor necrosis factor\u2010alpha induced cytokine production and nuclear factor\u2010kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno M","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_11_21_1","first-page":"1","article-title":"Regulatory effect of iguratimod on the balance of th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis","volume":"2015","author":"Xu Y","year":"2015","journal-title":"Mediat Inflamm"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2013.1468"},{"issue":"7","key":"e_1_2_11_23_1","first-page":"935","article-title":"Pharmacological studies of the new antiinflammatory agent 3\u2010formylamino\u20107\u2010methylsulfonylamino\u20106\u2010phenoxy\u20104H\u20101\u2010benzopyran\u20104\u2010o ne. 1st communication: antiinflammatory, analgesic and other related properties","volume":"42","author":"Tanaka K","year":"1992","journal-title":"Arzneimittel\u2010Forschung"},{"issue":"2","key":"e_1_2_11_24_1","first-page":"369","article-title":"Effects of iguramod combined with methotrexate on serum related cytokines and bone metabolism in patients with rheumatoid arthritis","volume":"34","author":"Yan XZ","year":"2018","journal-title":"J Changchun Univ Tradit Chin Med"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3668-8"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.14715\/cmb\/2016.62.13.8"},{"key":"e_1_2_11_27_1","first-page":"1","article-title":"Clinical efficacy of methotrexate combined with iguratimod on patients with rheumatoid arthritis and its influence on the expression levels of HOTAIR in serum","volume":"2021","author":"Tan J","year":"2021","journal-title":"BioMed Res Int"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:07:14Z","timestamp":1748002034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/iid3.932"],"URL":"https:\/\/doi.org\/10.1002\/iid3.932","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2023-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e932"}}